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Pharamacological Management During Carotid Endarterectomy
Maher Hamish, Manjit Gohel, Amanda Shepherd, Nathan J Howes, AlunH
Davies. Charing Cross Hospital, Greater London, United Kingdom
Introduction: The peri-operative use of antiplatelet, anticoagulant and
other drugs for patients undergoing carotid endarterectomy (CEA) is unclear
and consensus is lacking. This study aimed to assess the current practice of
European vascular surgeons with respect to antiplatelet and other medications.
Methods: An online survey was conducted of members of the Vascular
Society of Great Britain & Ireland and European Society for Vascular
Surgery in 2008. Surgeons were asked about their preferences for the
peri-operative administration of variousmedications for patients undergoing
carotid endarterectomy.
Results: Responses were received from 399 surgeons with a collective
annual throughput of 11500 CEA procedures. For symptomatic and
asymptomatic patients, 54/399(14%) and 94/399(24%) of surgeons would
stop aspirin before surgery and 205/399(54%) and 263/399(66%) of
surgeons would stop clopidogrel. Of surgeons who would stop clopidogrel,
84/205(40%) and 121/205(60%) would do so 7 days before surgery for
symptomatic and asymptomatic patients respectively. 12/399(3%) surgeons
would add one dose of clopidogrel the night before surgery. Intra-operative
Dextran was used selectively by 40/399(10%). Only 54/399(14%) would
delay surgery to commence a statin. For patients taking dual antiplatelet
medication, 13/399(3%) of surgeons routinely use intraoperative platelets.
Intraoperatively, 348/399(87%) used intravenous heparin and this was
reversed either routinely or selectively by 47/399(12%) and 60/399(15%)
respectively.
Conclusions: There are wide variations between vascular surgeons in
the pharamacological management of patients undergoing carotid endarter-
ectomy. Further clinical studies may help clarify the optimum management
strategy in this patient group.
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Percutaneous Angioplasty and Stenting as First-Choice Treatment in
Patients with Chronic Mesenteric Ischemia
Bram Fioole1, Joost Meijer1, Sebastiaan van Koeverden1, Frans L Moll2,
Michiel van de Rest1, Josua C van den Berg3, Jean-Paul P M de Vries1.
1Antonius Hospital Nieuwegein, Nieuwegein, Netherlands; 2University
Medical Center Utrecht, Utrecht, Netherlands; 3Ospedale Regionale di
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Objective: Open revascularization in patients with chronic mesenteric
ischemia (CMI) is considered the gold standard. Percutaneous angioplasty
and stenting (PTAS) is often reserved for patients not suitable for open
revascularization. In our institute, endovascular revascularization is the
first-choice treatment. We evaluated mortality, morbidity and patency in a
series of 54 consecutive patients with CMI.
Methods: A retrospective review was performed of all consecutive
patients treated for CMI from August 1994 to April 2008. Only symptom-
atic (6 months) patients treated for atherosclerotic CMI were included.
Patency was evaluated using CT-angiography. Kaplan-Meier curves were
used to calculate patient survival rates and patency rates of the treated
mesenteric arteries.
Results: Sixty-five mesenteric arteries (32 celiac, 26 superior mesenteric
and 7 inferior mesenteric arteries) were treated in 54 patients (27 men). In two
patients amajor complicationwas observed (following dissection of the superior
mesenteric artery (n1) and brachial artery (access site, n1), respectively, they
underwent endarterectomy and patch plasty of the dissected arteries). In 4
vessels the lesion could not be crossed endovascularly and they were deemed
immediate intention-to-treat failures. No 30-day mortality was observed. Me-
dian follow-up was 25 months. During follow-up 2 patients died of intestinal
ischemia and 13 of non-CMI related causes. Overall 1- and 2-year survival rates
were 89% and 79%. Symptomatic relief or weight gain was achieved in 81% of
patients. Primary 1- and 2-year patency rates were 85% and 67%, respectively;
primary assisted patency rateswere 90%and87%, respectively.During follow-up
4 patients underwent open revascularization due to failure of PTAS (1 to 47
months after the initial PTAS).
Conclusion: The initial technical success rate of PTAS as first-choice
treatment of CMI is 90%. The 2-years primary patency rates are reason-
able, and in-stent stenoses can often be treated successfully with renewed
endovascular techniques. Only few patients needed open revascularization
during follow-up.
Author Disclosures: B. Fioole, None; J. Meijer, None; S. van Koever-
den, None; F.L. Moll, None; M. van de Rest, None; J.C. van den Berg,
None; J.P.M. de Vries, None.PP9.
Endovascular Management of Chronic Mesenteric Ischemia
Michael B Hogan, Larry Richard Sprouse, II, Christopher LeSar, Luke
Erdoes, Daniel Fisher, Michael Greer, Paul Papillion, Ann Needham. Univ
Tennessee-Chattanooga, Chattanooga, TN
Objectives: Chronic Mesenteric Ischemia often presents in patients
who are malnourished and nutritionally compromised, often exacerbated
by a delay in diagnosis. These condition may predispose these patients to
increased surgical risks in open surgery. We present our results of
Endovascular management with percutaneous techniques in a large series
of patients.
Methods: A retrospective review of all patients diagnosed with chronic
mesenteric ischemia was performed. All procedures were performed in a
single group practice setting. Diagnoses was made by physical examination,
patient history and ultrasound examination. Patients were treated between
October 2003 through November 2008. Patients with acute mesenteric
ischemia were excluded Follow up was performed both in office and with
ultrasound. Analysis consisted of patient demographics, failure of treatment,
need for re-intervention as well as morbidity and mortality.
Results: Between October 2003 and November 2008 133 mesenteric
arteriograms were performed for patients in whom chronic mesenteric
ischemia was suspected. Twenty one patients had normal arteriograms, 112
patients and 128 vessels were treated with either angioplasty alone or with
stenting. Patient age ranged from 31 to 90 years old. Average age was 70.
Seventy-five percent of the patients were women. No deaths occurred within
the first 30 days. Six patients died within the first year, 2 from acute
mesenteric ischemia, 3 from unrelated causes and 1 from unknown cause.
Seventeen patients were lost to followup. Three patients after initial endo-
vascular treatment were eventually converted to an open procedure. None of
the patients required bowel resection.
Conclusions: Patients with chronic mesenteric ischemia can be man-
aged effectively with endovascular techniques. Many patients do require
reintervention to maintain patencey, however this can be accomplished with
minimal morbidity. Follow-up consisting of regular office visits and surveil-
lance ultrasound is an important adjunct in the management of these
complex patients.
Author Disclosures: M.B. Hogan, None; L.R. Sprouse, None; C. LeSar,
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Preoperative Clinical Determinants of Response to Renal Artery Stent-
ing: Who Will Benefit?
J. Gregory Modrall, Carlos H. Timaran, Bart L. Dolmatch, G. Patrick
Clagett, Clayton Trimmer. University of Texas Southwestern Medical Cen-
ter, Dallas, TX
Objective:Renal artery stenting (RAS) is the most commonmethod of
treating symptomatic renal artery stenosis despite few evidence-based guide-
lines to aid in patient selection. The goal of this study was to identify
predictors of blood pressure (BP) and renal function response that will aid in
patient selection for RAS.
Methods: The clinical outcomes of 149 patients who underwent
primary RAS between 2000 and 2008 were examined. A modification of
AHA guidelines defined individual patient responses to RAS: 1) BP respond-
ers  BP160/90 on a reduced number of anti-hypertensive medications
(MEDS) or reduction in diastolic BP to90mmHg on the sameMEDS; 2)
Renal function responders20% increase in eGFR.Median follow-up was
19 months.
Results:As a group, the cohort had a significant decrease in systolic and
diastolic BP with RAS (baseline vs. follow-up systolic BP: 155.62.5 vs.
139.72.3 mm Hg, P0.0001; baseline vs. follow-up diastolic BP:
79.11.5 mm Hg vs. 72.31.1 mm Hg, P0.0001) with no change in
MEDS (median number of MEDS at baseline vs. follow-up: 3 vs. 3,
P0.95). The cohort had no change in renal function with RAS (median
creatinine [CR] at baseline vs. follow-up: 1.4 vs. 1.3 mg/dL, P0.50).
Using rigorous criteria to determine individual responses to RAS, only 48 of
149 (32.2%) patients were BP responders and 22 of 149 (14.8%) patients
were renal function responders. Logistic regression analysis identified the
number of baseline MEDS (Odds Ratio [OR] 4.0, 95% CI 2.4-6.7,
P0.0001) and diastolic BP90 mm Hg (OR 13.3, 95% CI 4.0-44.0;
P0.0001) as independent predictors of a positive BP response. The BP
response rate, stratified by number of MEDS, is provided (Table) to assist
with patient selection for RAS. Preoperative CR 1.5 mg/dL was the only
independent predictor of renal function response (OR 5.3, 95%CI 1.7-16.6;
P0.004), although only 23.0% of patients with a CR 1.5 mg/dL were
renal function responders.
